Penumbra, Inc. Reports Third Quarter 2026 Financial Results
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
Revenue of $410.1 million in the third quarter of 2026, an increase of 15.6% compared to the third quarter of 2025.
Global thrombectomy revenue of $279.2 million in the third quarter of 2026, an increase of 18.1% compared to the third quarter of 2025. U.S. VTE revenue increased 26.0% compared to the same period a year ago.
Global embolization and access revenue of $131.0 million in the third quarter of 2026, an increase of 10.8% compared to the third quarter of 2025.
U.S. neuro revenue of $77.9 million in the third quarter of 2026, an increase of 19.3% compared to the third quarter of 2025.
Gross profit margin of 68.3% in the third quarter of 2026, an increase of 0.5% compared to the third quarter of 2025.
Total operating expenses of $229.6 million in the third quarter of 2026, comprised of R&D of $25.4 million and SG&A of $204.2 million, which includes $7.1 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.
Income from operations of $50.7 million and net income of $42.3 million in the third quarter of 2026.
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended September 30, 2026.
Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X .
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management’s attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking 1 statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. 2
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 254,282 $ 186,897 Marketable investments 419,330 357,919 Accounts receivable, net 195,216 190,021 Inventories 459,132 431,549 Prepaid expenses and other current 48,671 50,298 assets Total current assets 1,376,631 1,216,684 Property and equipment, net 156,443 117,436 Operating lease 164,346 173,587 right-of-use assets Finance lease right-of-use 23,510 25,972 assets Intangible assets, net 5,549 6,186 Goodwill 166,479 166,750 Deferred taxes 79,221 79,188 Other non-current assets 52,924 40,716 Total assets $ 2,025,103 $ 1,826,519 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 41,961 $ 34,736 Accrued liabilities 174,767 132,163 Current operating lease 14,706 13,841 liabilities Current finance lease 2,376 2,393 liabilities Total current liabilities 233,810 183,133 Non-current operating lease 173,277 182,751 liabilities Non-current finance lease 19,031 20,714 liabilities Other non-current 15,476 12,318 liabilities Total liabilities 441,594 398,916 Stockholders’ equity: Common stock 39 39 Additional paid-in capital 1,236,068 1,185,525 Accumulated other 37 4,348 comprehensive income Retained earnings 347,365 237,691 Total stockholders’ equity 1,583,509 1,427,603 Total liabilities and stockholders’ $ 2,025,103 $ 1,826,519 equity
Full text with the tables
Exhibit 99.1
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the
world’s leading thrombectomy company, today reported financial results for the
third quarter ended September 30, 2026.
•
Revenue of $410.1 million in the third quarter of 2026, an increase of 15.6%
compared to the third quarter of 2025.
•
Global thrombectomy revenue of $279.2 million in the third quarter of 2026, an
increase of 18.1% compared to the third quarter of 2025. U.S. VTE revenue
increased 26.0% compared to the same period a year ago.
•
Global embolization and access revenue of $131.0 million in the third quarter of
2026, an increase of 10.8% compared to the third quarter of 2025.
•
U.S. neuro revenue of $77.9 million in the third quarter of 2026, an increase of
19.3% compared to the third quarter of 2025.
•
Gross profit margin of 68.3% in the third quarter of 2026, an increase of 0.5%
compared to the third quarter of 2025.
•
Total operating expenses of $229.6 million in the third quarter of 2026,
comprised of R&D of $25.4 million and SG&A of $204.2 million, which includes
$7.1 million of acquisition-related expenses associated with the pending
acquisition of Penumbra, Inc. by Boston Scientific Corporation.
•
Income from operations of $50.7 million and net income of $42.3 million in the
third quarter of 2026.
Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation
(NYSE: BSX), the Company will not be providing financial guidance for the full
year 2026 or hosting a conference call to discuss financial results for the
three months ended September 30, 2026.
About Penumbra
Penumbra, Inc., the world’s leading thrombectomy company, is focused on
developing the most innovative technologies for challenging medical conditions
such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and
acute limb ischemia. Our broad portfolio, which includes computer assisted
vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe
with speed, safety and simplicity. By pioneering these innovations, we support
healthcare providers, hospitals and clinics in more than 100 countries, working
to improve patient outcomes and quality of life. For more information, visit
www.penumbrainc.com and connect on Instagram, LinkedIn, and X .
Forward-Looking Statements
Except for historical information, certain statements in this press release are
forward-looking in nature and are subject to risks, uncertainties and
assumptions about us. Our business and operations are subject to a variety of
risks and uncertainties and, consequently, actual results may differ materially
from those projected by any forward-looking statements. Factors that could cause
actual results to differ from those projected include, but are not limited to:
the risk that the pending acquisition by Boston Scientific Corporation will not
be completed in the expected timeframe or at all, including the risk that
required regulatory approvals will not be obtained; potential adverse effects to
our business during the pendency of the acquisition, such as employee departures
or diversion of management’s attention from our business; failure to sustain or
grow profitability or generate positive cash flows; failure to effectively
introduce and market new products; delays in product introductions; significant
competition; inability to further penetrate our current customer base, expand
our user base and increase the frequency of use of our products by our
customers; inability to achieve or maintain satisfactory pricing and margins;
manufacturing difficulties; permanent write-downs or write-offs of our inventory
or other assets; product defects or failures; unfavorable outcomes in clinical
trials; inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; potential adverse regulatory actions; and the potential
impact of any acquisitions, mergers, dispositions, joint ventures or investments
we may make. These risks and uncertainties, as well as others, are discussed in
greater detail in our filings with the Securities and Exchange Commission
("SEC"), including our Annual Report on Form 10-K for the year ended December
31, 2025 filed with the SEC on February 25, 2026. There may be additional risks
of which we are not presently aware or that we currently believe are immaterial
which could have an adverse impact on our business. Any forward-looking
1
statements are based on our current expectations, estimates and assumptions
regarding future events and are applicable only as of the dates of such
statements. We make no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may change.
2
Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash equivalents $ 254,282 $ 186,897
Marketable investments 419,330 357,919
Accounts receivable, net 195,216 190,021
Inventories 459,132 431,549
Prepaid expenses and other
current 48,671 50,298
assets
Total current assets 1,376,631 1,216,684
Property and equipment, net 156,443 117,436
Operating lease 164,346 173,587
right-of-use assets
Finance lease right-of-use 23,510 25,972
assets
Intangible assets, net 5,549 6,186
Goodwill 166,479 166,750
Deferred taxes 79,221 79,188
Other non-current assets 52,924 40,716
Total assets $ 2,025,103 $ 1,826,519
Liabilities and
Stockholders’ Equity
Current liabilities:
Accounts payable $ 41,961 $ 34,736
Accrued liabilities 174,767 132,163
Current operating lease 14,706 13,841
liabilities
Current finance lease 2,376 2,393
liabilities
Total current liabilities 233,810 183,133
Non-current operating lease 173,277 182,751
liabilities
Non-current finance lease 19,031 20,714
liabilities
Other non-current 15,476 12,318
liabilities
Total liabilities 441,594 398,916
Stockholders’ equity:
Common stock 39 39
Additional paid-in capital 1,236,068 1,185,525
Accumulated other 37 4,348
comprehensive income
Retained earnings 347,365 237,691
Total stockholders’ equity 1,583,509 1,427,603
Total liabilities and
stockholders’ $ 2,025,103 $ 1,826,519
equity
3
Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
Three Nine
Months Months
Ended Ended
Septemb… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Reven… $ 410,145 $ 354,685 $ 1,174,9… $ 1,018,…
Cost
of 129,842 114,269 376,291 337,971
reven…
Gross 280,303 240,416 798,658 680,309
profit
Opera…
expen…
Resea…
and 25,361 22,677 73,139 67,972
devel…
Sales,
gener… 204,203 168,901 595,507 482,321
and
admin…
Total
opera… 229,564 191,578 668,646 550,293
expen…
Income
from 50,739 48,838 130,012 130,016
opera…
Inter…
and
other 5,577 3,487 14,179 11,477
incom…
net
Income
before 56,316 52,325 144,191 141,493
income
taxes
Provi…
for 14,037 6,474 34,517 11,149
income
taxes
Net $ 42,279 $ 45,851 $ 109,674 $ 130,344
income
Net
income
per
share:
Basic $ 1.07 $ 1.17 $ 2.79 $ 3.36
Dilut… $ 1.07 $ 1.17 $ 2.77 $ 3.32
Weigh…
avera…
shares
outst…
Basic 39,402,… 39,078… 39,344,… 38,827…
Dilut… 39,620,… 39,302… 39,598,… 39,250…
4
Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions
(unaudited)
(in thousands, except for percentages)
Three
Months
Ended
Septem…
30, Change
──────────────────────────────────────────────────────────────────────────────
2026 2025 $ %
United $ 324,248 $ 275,029 $ 49,219 17.9 %
States
Intern… 85,897 79,656 6,241 7.8 %
Total $ 410,145 $ 354,685 $ 55,460 15.6 %
Nine
Months
Ended
Septem…
30, Change
──────────────────────────────────────────────────────────────────────────────
2026 2025 $ %
United $ 926,080 $ 792,707 $ 133,373 16.8 %
States
Inter… 248,869 225,573 23,296 10.3 %
Total $ 1,174,… $ 1,018,… $ 156,669 15.4 %
Penumbra, Inc.
Reconciliation of Revenue Growth by Product Categories
(unaudited)
(in thousands, except for percentages)
Three
Months
Ended
Septem…
30, Change
──────────────────────────────────────────────────────────────────────────────
2026 2025 $ %
Thromb… $ 279,157 $ 236,422 $ 42,735 18.1 %
Emboli…
and 130,988 118,263 12,725 10.8 %
Access
Total $ 410,145 $ 354,685 $ 55,460 15.6 %
Nine
Months
Ended
Septem…
30, Change
──────────────────────────────────────────────────────────────────────────────
2026 2025 $ %
Throm… $ 792,055 $ 693,222 $ 98,833 14.3 %
Embol…
and 382,894 325,058 57,836 17.8 %
Access
Total $ 1,174,… $ 1,018,… $ 156,669 15.4 %
Investor Relations
Penumbra, Inc.
[email protected]
Source: Penumbra, Inc.
5